3P Biopharmaceuticals increases its microbial production capacity with the installation of a 500 L fermenter.
The fermenter adds to 3P's capacity for manufacturing biological medicinal products using microbial technology.
3P Biopharmaceuticals (3P), a leading contract development and manufacturing organization (CDMO) specializing in process development and cGMP manufacturing for biological products complements its existing capacity for protein production from bacteria and yeast through installation of a new 500-litre stainless steel fermenter with fermentation technology.
The addition of this new capacity complements the existing three fermentation lines that carry out drug production from bacteria and yeast. This means that 3P Biopharmaceuticals now has availability of 10 L, 100L, 500L and 1,000 L capacities for microbial manufacturing.
The new fermenter that fully complies with the regulatory standards of Good Manufacturing Practices (GMPs) of the European Medicines Agency (EMA), will allow the Navarran biotech company to multiply by five the production capacity of one of its three microbial manufacturing lines.
Dámaso Molero, CEO of 3P Biopharmaceuticals is very positive and states that “the demand for microbial protein manufacturing capacity is increasing nowadays and customers require more capacity for their projects. At 3P we will always be ready to adapt to meet all of their needs”.
Elena Erroba, Business Development Director at 3P explains: “3P has a proven and established reputation as a leading CDMO in the manufacture of biologic medicines with microbial technology and the expansion of our capacity with this new 500 L fermenter allows us to support new and existing customers in the clinical development and commercial supply of their therapies”.
With the recent renovations that 3P has carried out over the last three years, its facilities now total 10,500 m2. The main purpose of the remodelling is to further expand its production capacity and increase the efficiency of its process development and manufacturing services.
In 2022, 3P Biopharmaceuticals celebrated its 15th anniversary and closed the year with a turnover of more than 42 million euros and a 22% growth. 3P now has more than 350 employees and is currently collaborating with more than 25 international clients, consolidating ongoing projects, and initiating new ones.
View the full press release here
